NHI

National Health Investors Inc

Add to Watchlist

Advanced Chart

75.260

+0.34(0.454%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

75.560

Open

75.000

VWAP

75.22

Vol

195.96K

Mkt Cap

3.57B

Low

74.860

Amount

14.74M

EV/EBITDA(TTM)

24.48

Total Shares

43.42M

4.67B

EV/OCF(TTM)

22.00

P/S(TTM)

9.78

National Health Investors, Inc. is a real estate investment trust. The Company specializes in sales, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment consists of real estate investments, leases, and mortgage and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities and a hospital. It has approximately 193 healthcare real estate properties located in 33 states and leased primarily pursuant to triple-net leases to 27 tenants. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. This segment has over 15 properties located in eight states with a combined 1,732 units.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

89.52M

+7.93%

92.50M

+7.86%

96.34M

+7.89%

Estimates Revision

The market is revising Downward the revenue expectations for National Health Investors, Inc. (NHI) for FY2025, with the revenue forecasts being adjusted by -3.17% over the past three months. During the same period, the stock price has changed by -0.40%.

Revenue Estimates for FY2025

Revise Downward

-3.17%

In Past 3 Month

Stock Price

Go Down

-0.40%

In Past 3 Month

5 Analyst Rating

4.97% Upside

Wall Street analysts forecast NHI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NHI is 79.00 USD with a low forecast of 76.00 USD and a high forecast of 81.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

4.97% Upside

Current: 75.260

Low

76.00

Averages

79.00

High

81.00

4.97% Upside

Current: 75.260

Low

76.00

Averages

79.00

High

81.00

KeyBanc

Sector Weight -> Overweight

upgrade

$80

2025-07-10

Reason

KeyBanc

Price Target

$80

2025-07-10

upgrade

Sector Weight -> Overweight

Reason

KeyBanc upgraded National Health Investors to Overweight from Sector Weight with an $80 price target. The firm says the company has \"multiple value-creation opportunities\" to drive upside to estimates. It sees incremental unscheduled deferral repayments beyond what is assumed in guidance and better execution on investments relative to expectations. National Health has the potential to enhance its internal growth profile and drive upside to 2025 guidance and consensus estimates, the analyst tells investors in a research note.

Truist

Hold

Buy

upgrade

$77

2025-07-02

Reason

Truist

Price Target

$77

2025-07-02

upgrade

Hold

Buy

Reason

Truist upgraded National Health Investors to Buy from Hold with an unchanged price target of $77. The analyst, who expects skilled nursing rent coverage and senior housing operating portfolio fundamentals to continue to improve, notes that National Health is one of the lowest-levered REITs in its coverage universe and still has among the highest forecasted three- and five-year earnings growth rates.

Truist Securities

Michael Lewis

Hold

Maintains

$70 → $76

2025-03-19

Reason

Truist Securities

Michael Lewis

Price Target

$70 → $76

2025-03-19

Maintains

Hold

Reason

Truist analyst Michael Lewis raised the firm's price target on National Health Investors to $76 from $70 but keeps a Hold rating on the shares. The firm is adjusting its model to reflect the REIT's more advantageous cost of debt and equity capital, noting that the market is giving National Health the green light to make new investments, the analyst tells investors in a research note. Truist adds however that the stock is not cheap relative to peers' or its own history.

Wedbush

Richard Anderson

Buy

Reiterates

$88

2025-03-17

Reason

Wedbush

Richard Anderson

Price Target

$88

2025-03-17

Reiterates

Buy

Reason

Truist Securities

Michael Lewis

Hold

Maintains

$78 → $72

2024-12-23

Reason

Truist Securities

Michael Lewis

Price Target

$78 → $72

2024-12-23

Maintains

Hold

Reason

Truist analyst Michael Lewis lowered the firm's price target on National Health Investors to $72 from $78 and keeps a Hold rating on the shares. The firm is adjusting its model after the pullback in the stock price, though leaving its FFO multiple and net asset value premium relatively unchanged, the analyst tells investors in a research note. Truist adds it is positive on the REIT's healthcare property type diversification, relatively high exposure to private payment for services from residents, a low-levered balance sheet, and an attractive well-covered dividend yield.

Wells Fargo

John Kilichowski

Buy

Hold

Initiates

$81 → $86

2024-10-01

Reason

Wells Fargo

John Kilichowski

Price Target

$81 → $86

2024-10-01

Initiates

Buy

Hold

Reason

Wells Fargo downgraded National Health Investors to Equal Weight from Overweight with a price target of $86, up from $81, following analyst coverage transfer. While still positive on the National Health Investors story, the firm prefers the other SNFs here as it prefers their growth stories. Wells notes Q2 saw some weakness in the quarter.

See All Ratings

Valuation Metrics

The current forward P/E ratio for National Health Investors Inc (NHI.N) is 23.21, compared to its 5-year average forward P/E of 20.53. For a more detailed relative valuation and DCF analysis to assess National Health Investors Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

20.53

Current PE

23.21

Overvalued PE

23.71

Undervalued PE

17.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

15.22

Current EV/EBITDA

15.08

Overvalued EV/EBITDA

16.57

Undervalued EV/EBITDA

13.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.80

Current PS

9.39

Overvalued PS

9.99

Undervalued PS

7.60